Related Experiment Videos

Development of Recombinant HSV-Based Vaccine Vectors.

Richard Voellmy1,2, David C Bloom3, Nuria Vilaboa4,5

  • 1HSF Pharmaceuticals SA, La Tour-de-Peilz, Switzerland. rvoellmy@hsfpharma.com.

Summary

Developing a novel herpes simplex virus (HSV) vaccine using a conditionally replication-competent HSV-1 vector offers a promising strategy. This innovative vaccine approach enhances immune response while maintaining safety, addressing previous vaccine development challenges.

Related Concept Videos